|
시장보고서
상품코드
2148400
급성 골수성 백혈병 치료제 시장 : 질환별, 치료법별, 투여 경로별, 최종사용자별, 지역별Acute Myeloid Leukemia Therapeutics Market, By Disease Type, By Treatment Type, By Route of Administration, By End User, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
급성 골수성 백혈병 치료제 시장은 2026년에 37억 6,000만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 72억 3,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 9.8%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 37억 6,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 9.80% | 2033년 시장 규모 예측 : | 72억 3,000만 달러 |
급성 골수성 백혈병(AML)은 골수에서 발생하는 치명적인 혈액암입니다. 이는 미성숙한 골수계 세포가 통제 불가능하게 증식하여 정상 혈액 세포의 생성을 방해하는 질환입니다. 분자 수준의 이질성과 여러 유전적 변이와의 연관성으로 인해 AML은 보다 전문적인 치료 전략이 필요한 복잡한 질환입니다.
급성 골수성 백혈병의 치료 양상은 화학요법에서 표적 치료, 면역 치료, 그리고 정밀 의학으로 전환되고 있으며, FLT3, IDH1/2, BCL-2, 메닌 억제제의 등장으로 치료 선택지가 확대되고 있습니다. 전 세계 급성 골수성 백혈병 치료제 시장의 주요 성장 동인으로는 질병 부담의 증가, 임상 연구, 그리고 새로운 치료법에 대한 투자가 꼽힙니다.
시장 역학
전 세계 급성 골수성 백혈병 치료제 시장은 고령화 사회에서 급성 골수성 백혈병(AML)의 유병률 증가, 유전체 프로파일링의 발전, 그리고 돌연변이 특이적 표적 치료법의 적용 확대에 힘입어 성장하고 있습니다. 또한 신속한 규제 심사 절차의 도입으로 새로운 치료법의 개발 및 상용화가 가능해졌으며, 의료 분야에 대한 투자 확대로 최첨단 암 치료에 대한 접근성이 향상되고 있습니다.
그러나 급성 골수성 백혈병 치료제 시장의 성장은 고액의 치료비, 분자 수준의 복잡성, 약물 내성 및 질병 재발과 같은 요인에 의해 제약을 받고 있습니다. 그럼에도 불구하고 메닌 억제제, 항체-약물 접합체(ADC), 이중특이성 항체, CAR-T 요법 및 새로운 병용 요법 등 지속적으로 확대되고 있는 파이프라인에는 큰 기회가 존재합니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 해설하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공합니다.
- 본 조사에서는 다음 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 급성 골수성 백혈병 치료제 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서에서 얻은 인사이트를 바탕으로 마케팅 담당자 및 기업 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 ‘글로벌 급성 골수성 백혈병 치료제 시장’ 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 급성 골수성 백혈병 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활한 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 급성 골수성 백혈병 치료제 시장 : 질환 유형별, 2021-2033년
제5장 세계의 급성 골수성 백혈병 치료제 시장 : 치료 유형별, 2021-2033년
제6장 세계의 급성 골수성 백혈병 치료제 시장 : 투여 경로별, 2021-2033년
제7장 세계의 급성 골수성 백혈병 치료제 시장 : 최종사용자별, 2021-2033년
제8장 세계의 급성 골수성 백혈병 치료제 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고 문헌 및 조사 방법
KSA 26.10.20Acute Myeloid Leukemia Therapeutics Market is estimated to be valued at USD 3.76 Bn in 2026 and is expected to reach USD 7.23 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.76 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 7.23 Bn |
Acute Myeloid Leukemia (AML) is a lethal blood cancer that arises in the bone marrow. It is an uncontrolled growth of immature myeloid cells with interference to the normal blood cell production. The molecular heterogeneity and association with multiple genetic alterations makes AML a complex disease requiring more specialized treatment strategies.
The acute myeloid leukemia treatment landscape has moved from chemotherapy to targeted therapy, immunotherapies and precision-based therapies, with the addition of FLT3, IDH1/2, BCL-2 and menin inhibitors broadening the treatment options. Key drivers for the global acute myeloid leukemia therapeutics market include the rising burden of the disease, clinical research, and investment in new therapies.
Market Dynamics
The global acute myeloid leukemia therapeutics market is driven by the increasing prevalence of AM acute myeloid leukemia in aging populations, advancements in genomic profiling, and the enhanced application of mutation-specific targeted therapy. Moreover, expedited regulatory pathways are enabling the development and commercialization of new treatments, and greater healthcare investment is improving the access to cutting-edge oncology care.
However, the growth of acute myeloid leukemia therapeutics market is limited by factors such as high treatment cost, molecular complexity, resistance to drugs and the recurrence of the disease. Nevertheless, significant opportunities exist in growing pipeline of menin inhibitors, antibody-drug conjugates, bispecific antibodies, CAR-T therapies and new combination regimens.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global acute myeloid leukemia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AbbVie Inc., Astellas Pharma Inc., Bristol Myers Squibb Company, Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Rigel Pharmaceuticals, Inc., and Servier Pharmaceuticals LLC
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global acute myeloid leukemia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute myeloid leukemia therapeutics market
Market Segmentation
- Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Myeloblastic Leukemia
- Promyelocytic Leukemia
- Myelomonocytic Leukemia
- Monocytic Leukemia
- Others
- Treatment Type Insights (Revenue, USD Bn, 2021 - 2033)
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Combination Therapy
- Supportive Care
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Parenteral
- Oral
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Oncology Centers
- Clinics and Ambulatory Care Centers
- Homecare Settings
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AbbVie Inc.
- Astellas Pharma Inc.
- Bristol Myers Squibb Company
- Daiichi Sankyo Company, Limited
- Jazz Pharmaceuticals plc
- Novartis AG
- Pfizer Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Rigel Pharmaceuticals, Inc.
- Servier Pharmaceuticals LLC
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Acute Myeloid Leukemia Therapeutics Market, By Disease Type
- Global Acute Myeloid Leukemia Therapeutics Market, By Treatment Type
- Global Acute Myeloid Leukemia Therapeutics Market, By Route of Administration
- Global Acute Myeloid Leukemia Therapeutics Market, By End User
- Global Acute Myeloid Leukemia Therapeutics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Industry Trends
4. Global Acute Myeloid Leukemia Therapeutics Market, By Disease Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Myeloblastic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Promyelocytic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Myelomonocytic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Monocytic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Acute Myeloid Leukemia Therapeutics Market, By Treatment Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Combination Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Supportive Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Acute Myeloid Leukemia Therapeutics Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Acute Myeloid Leukemia Therapeutics Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Specialty Oncology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinics and Ambulatory Care Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Acute Myeloid Leukemia Therapeutics Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo Company, Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Jazz Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rigel Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Servier Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
